Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease

BACKGROUND: Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevacizumab is still very controversial. We report the outcome of 6 eyes of 4 premature infants with ROP stage 3 plus disease treated with ranibizumab monotherapy. METHODS: Six eyes of 4 premature infants with threshold ROP...

Descripción completa

Detalles Bibliográficos
Autores principales: Menke, Marcel N, Framme, Carsten, Nelle, Mathias, Berger, Markus R, Sturm, Veit, Wolf, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365803/
https://www.ncbi.nlm.nih.gov/pubmed/25886603
http://dx.doi.org/10.1186/s12886-015-0001-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365803/
https://www.ncbi.nlm.nih.gov/pubmed/25886603
http://dx.doi.org/10.1186/s12886-015-0001-7

Ejemplares similares